67973-32-4

Basic information

• Product Name: 3,5-DIBROMO-4-METHYLBENZOIC ACID
• Synonyms: 3,5-DIBROMO-4-METHYLBENZOIC ACID;TIMTEC-BB SBB001202;3,5-Dibromo-p-toluic acid;3,5-DIBROMO-4-METHYLBENZOIC ACID 98+%;Benzoic acid, 3,5-dibroMo-4-Methyl-
• CAS NO: 67973-32-4
• Molecular Formula: C₈H₆Br₂O₂
• Molecular Weight: 293.94
• EINECS: -0
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;Benzoic acid;Acids & Esters;Bromine Compounds
• Mol File: 67973-32-4.mol
• Article Data: 1

Chemical Properties

• Melting Point: 242°C
• Boiling Point: 374.6 °C at 760 mmHg
• Flash Point: 180.3 °C
• Appearance: /
• Density: 1.951 g/cm³
• Vapor Pressure: 2.82E-06mmHg at 25°C
• Refractive Index: 1.627
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.59±0.10(Predicted)
• BRN: 2577656
• CAS DataBase Reference: 3,5-DIBROMO-4-METHYLBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIBROMO-4-METHYLBENZOIC ACID(67973-32-4)
• EPA Substance Registry System: 3,5-DIBROMO-4-METHYLBENZOIC ACID(67973-32-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 67973-32-4(Hazardous Substances Data)

Usage

General Description

3,5-DIBROMO-4-METHYLBENZOIC ACID is a chemical compound with the molecular formula C8H6Br2O2. It is a derivative of benzoic acid, with two bromine atoms attached to the 3 and 5 positions, and a methyl group attached to the 4 position of the benzene ring. 3,5-DIBROMO-4-METHYLBENZOIC ACID is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and dyes. It has also been studied for its potential antimicrobial and antifungal properties. Additionally, 3,5-DIBROMO-4-METHYLBENZOIC ACID is used as a building block in the production of advanced materials and specialty chemicals.

InChI:InChI=1/C8H6Br2O2/c1-4-6(9)2-5(8(11)12)3-7(4)10/h2-3H,1H3,(H,11,12)

Upstream product

• 74896-66-5 Methyl 3,5-Dibromo-4-methylbenzoate 
• 122-00-9 para-methylacetophenone 
• 13194-73-5 3,5-dibromo-4-methylaniline 
• 116596-20-4 bromoxynil 
• 55548-03-3 1-(3,5-dibromo-4-methyl-phenyl)-ethanone 

Downstream Products

• 1229245-24-2 3,5-dibromo-N-cyclopropyl-4-methylbenzamide 
• 1373120-94-5 C₁₀H₈Br₂N₂O 
• 871465-06-4 C₂₀H₃₀N₆O 
• 1194491-85-4 N-[3-bromo-5-(3-methoxypropyl)-4-methylbenzyl]cyclopropanamine mesylate 
• 1312350-29-0 (3R,4S)-N-[3-bromo-5-(3-methoxypropyl)-4-methylbenzyl]-N-cyclopropyl-4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-piperidine-3-carboxamide 
• 1312350-26-7 tert-butyl (3R,4S)-3-{[[3-bromo-5-(3-methoxypropyl)-4-methylbenzyl](cyclopropyl)amino]carbonyl}-4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)piperidine-1-carboxylate 
• 1312350-32-5 (3R,4S)-N-[3-bromo-5-(3-methoxypropyl)-4-methylbenzyl]-N-cyclopropyl-4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-piperidine-3-carboxamide hydrochloride 
• 871339-75-2 phenylmethyl 4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]benzoate 
• 871339-79-6 1,1-dimethylethyl {4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}carbamate 
• 871339-78-5 4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]benzoyl azide 
• 871339-76-3 4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]benzoic acid 
• 871339-77-4 4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]benzoyl fluoride 
• 871339-80-9 N-{5-amino-2-methyl-3-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}-2,2,2-trifluoro-N-(2-pyrrolidin-1-ylethyl)acetamide 
• 871339-81-0 N-{5-bromo-2-methyl-3-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}-2,2,2-trifluoro-N-(2-pyrrolidin-1-ylethyl)acetamide 

Relevant articles and documents

Pyrazolopyrimidines as dual Akt/p70S6K inhibitors

Activation of the PI3K/Akt/mTOR kinase pathway is frequently associated with human cancer. Selective inhibition of p70S6Kinase, which is the last kinase in the PI3K pathway, is not sufficient for strong tumor growth inhibition and can lead to activation of upstream proteins including Akt through relief of a negative feedback loop. Targeting multiple sites in the PI3K pathway might be beneficial for optimal activity. In this manuscript we report the design of dual Akt/p70S6K inhibitors and the evaluation of the lead compound 11b in vivo, which was eventually advanced into clinical development.